BDX Shares BCAL Diagnostics Limited
ASX · ASXLast in our picks 2026-10-04 — not in the current list; analysis below is from that screen
Undervalued diagnostics play with room for rerating on execution and market traction.
Future value: $0.12 (+37.93%) · 6-12 months
Signal breakdown
- ▸Potential upside, but liquidity and visibility are modest.
- ▸Above 50-day MA (+25.14%)
- ▸Volume 2.95× average — accumulation
- ▸~38% upside to price target
Is BDX a buy right now?
Trend: BDX is trading above the 50-day average (+0.00%), RSI 42 — neutral momentum, with a 3-month return of +9.59%.
Valuation & quality: fundamentals show net margin 0.0%, return on equity -273.3%, revenue growth -14.7% year on year.
Our screen: BUY (score 3) — Undervalued diagnostics play with room for rerating on execution and market traction.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -25.00% | -11.10% | +0.00% | +0.00% | -12.50% | +0.00% | +28.60% | -11.10% |
Fundamentals
Technical signals
About BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia.
Sector: Healthcare · Industry: Diagnostics & Research · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.